Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol. Its primary commercial product is Korlym (mifepristone) for hypercortisolism (Cushing's syndrome), for which an authorized generic was launched in June 2024. The company is advancing a pipeline of selective cortisol modulators, including relacorilant (hypercortisolism and ovarian cancer), dazucorilant (ALS), and miricorilant (MASH).
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | 2025 (YTD) | 2024 (YTD) | Change |
|---|---|---|---|
| Net Product Revenue | $351.6 million | $310.6 million | +13.2% |
| Cost of Sales | $5.8 million | $5.1 million | +13.7% |
| Gross Margin | 98.3% | 98.4% | -0.1% |
| Operating Expenses | $321.6 million | $245.5 million | +31.0% |
| Income from Operations | $30.1 million | $65.1 million | -53.8% |
| Net Income | $55.7 million | $63.3 million | -12.0% |
| Diluted EPS | $0.46 | $0.57 | -19.3% |
| Cash & Marketable Securities | $515.0 million | $603.2 million (Dec 31, 2024) | -14.6% |
| Operating Cash Flow | $49.1 million | $64.9 million | -24.3% |
Liquidity: As of June 30, 2025, the company held $102.7 million in cash and cash equivalents and $412.3 million in marketable securities. There is no long-term debt reported.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13.2% year-over-year, driven by a 36.8% increase in sales volume. This volume growth was partially offset by a 17.3% decrease in average selling price due to the introduction of the authorized generic version of Korlym.
- Expense Expansion: Operating expenses rose significantly, primarily due to increased Selling, General, and Administrative (SG&A) expenses ($194.5M vs. $123.2M) to support commercialization and marketing, and higher Research and Development (R&D) expenses ($121.2M vs. $117.3M) driven by clinical program advancement.
- Tax Benefit: The company recorded an income tax benefit of $14.4 million for the six months ended June 30, 2025, compared to an expense of $13.3 million in the prior year. This shift was primarily due to increased stock-based compensation deductions and lower year-to-date pretax income.
- Share Repurchases: The company aggressively returned capital to shareholders, spending $130.5 million on share repurchases under its Stock Repurchase Program during the first half of 2025, compared to $4.0 million in the same period in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Relacorilant (Hypercortisolism): An NDA was submitted in December 2024. The FDA accepted the filing in March 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025.
- Relacorilant (Ovarian Cancer): An NDA was submitted in July 2025 for relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, following positive Phase 3 ROSELLA trial results showing a 30% reduction in risk of disease progression.
- Dazucorilant (ALS): While the Phase 2 DAZALS trial did not meet its primary endpoint (ALSFRS-R), exploratory analyses showed a statistically significant 84% reduction in risk of early death for patients on the 300 mg dose. A long-term extension study is ongoing.
- Legislative Impact: The company notes the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which allows immediate expensing of R&D and may reduce current taxes payable and deferred tax assets in the second half of 2025.
Risks and Contingencies
- Patent Litigation: Corcept is appealing a District Court ruling that Teva's generic Korlym does not infringe Corcept's patents. Teva launched its generic in January 2024. Corcept also faces antitrust litigation from Teva and a separate lawsuit from insurance providers (Aetna, etc.) alleging unfair business practices.
- Regulatory & Political Risk: Risks include potential restrictions on mifepristone due to its use in abortion (despite Corcept's product being for Cushing's), government funding cuts to agencies like the FDA, and the impact of the Inflation Reduction Act (IRA) on Medicare pricing starting in 2026.
- Supply Chain: The company relies on a single specialty pharmacy (Optime) for dispensing and patient support, representing over 99% of revenue collection.
Investor Verification Checklist
- Generic Competition Impact: Verify the trajectory of revenue mix between branded Korlym and the authorized generic, and monitor the outcome of the patent appeal against Teva.
- Relacorilant Approval Timeline: Confirm the status of the FDA review for the hypercortisolism NDA (PDUFA date: Dec 30, 2025) and the newly submitted ovarian cancer NDA.
- ALS Trial Data: Scrutinize the long-term extension data for dazucorilant to validate the survival benefit observed in the exploratory analysis of the DAZALS trial.
- Cash Burn vs. Repurchases: Assess the sustainability of the current share repurchase pace ($130.5M in H1 2025) against operating cash flow ($49.1M in H1 2025) and future R&D capital requirements.
- Legal Exposure: Monitor developments in the Teva antitrust litigation and the Aetna/insurance provider lawsuit, which could result in significant financial penalties or operational restrictions.